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Cystic fibrosis arises from the misfolding and
premature degradation of CFTRDF508, a Cl
ion channel with a single amino acid deletion.
Yet, the quality-control machinery that selects
CFTRDF508 for degradation and the mecha-
nism for its misfolding are not well defined.
We identified an ER membrane-associated
ubiquitin ligase complex containing the E3
RMA1, the E2 Ubc6e, and Derlin-1 that cooper-
ates with the cytosolic Hsc70/CHIP E3 complex
to triage CFTR andCFTRDF508. Derlin-1 serves
to retain CFTR in the ER membrane and inter-
acts with RMA1 and Ubc6e to promote CFTR’s
proteasomal degradation. RMA1 is capable of
recognizing folding defects in CFTRDF508 co-
incident with translation, whereas the CHIP E3
appears to act posttranslationally. A folding de-
fect in CFTRDF508 detected by RMA1 involves
the inability of CFTR’s second membrane-
spanning domain to productively interact with
amino-terminal domains. Thus, the RMA1 and
CHIP E3 ubiquitin ligases act sequentially in
ER membrane and cytosol to monitor the fold-
ing status of CFTR and CFTRDF508.
INTRODUCTION
CFTR is a Cl ion channel that is localized to the apical
surface of epithelial cells that line ducts and lung airways
(Riordan et al., 1989). Around 90% of cystic fibrosis (CF)
patients inherit at least one copy of the CFTRDF508 allele,
which is missing F508 from nucleotide binding domain
(NBD) I. CFTRDF508 is synthesized and properly inserted
into the membrane of the endoplasmic reticulum (ER), but
it fails to reach the native state and accumulates in a kinet-ically trapped, but foldable, conformation (Cyr, 2005;
Younger et al., 2004). Kinetically trapped CFTRDF508 is
recognized by the ER quality-control machinery (ERQC),
polyubiquitinated, retrotranslocated, and degraded by
the proteasome (Cheng et al., 1990; Denning et al.,
1992; Jensen et al., 1995; Kreda et al., 2005; Meacham
et al., 2001;Ward et al., 1995). The network of quality-con-
trol (QC) factors that triages nascent CFTR and other ER
proteins is not well defined, but is generally known as
the ER-associated degradation pathway (ERAD)
(McCracken and Brodsky, 1996). Loss of CFTR function
at the cell surface is the cause for mortality in CF patients
because it alters the hydration of the mucosal layer that
lines airway epithelia and gives rise to persistent microbial
infections with resultant lung fibrosis and failure (Rowe
et al., 2005).
Folding defects exhibited by CFTRDF508 are condi-
tional, and treatment of cells with chemical or pharmaco-
logical chaperones promotes its proper folding and chan-
nel function at the plasma membrane (Brown et al., 1996;
Denning et al., 1992). Corrected CFTRDF508 has a mark-
edly shorter half-life at the cell surface than CFTR (Sharma
et al., 2004), yet patients that express low levels of func-
tional CFTR display a mild disease phenotype (Welsh
and Ostedgaard, 1998). Therefore, agents that promote
CFTRDF508 folding or block the degradation of folded
CFTRDF508 have potential as CF therapeutics (Pede-
monte et al., 2005; Van Goor et al., 2006). Guidance for
the development of CF therapeutics requires a basic
understanding of the mechanisms for CFTRDF508 mis-
folding and the identification of the ERQC machinery
that selects CFTRDF508 for ERAD.
CFTR folding is complex because it is a 1480 residue
glycomembrane protein, and its two membrane-spanning
domains (MSDs), two cytoplasmic NBDs, and a regulatory
domain (R domain) must interact with each other to form
a Cl ion channel (Ostedgaard et al., 1997; Xiong et al.,
1997). In most cell types tested, the biosynthesis of CFTR
takes10min, and theassemblyofCFTRandCFTRDF508
into a channel is inefficient, with 60%–75% of CFTRCell 126, 571–582, August 11, 2006 ª2006 Elsevier Inc. 571
and nearly 99% of newly synthesized CFTRDF508 be-
ing degraded (Ward and Kopito, 1994). The folding ef-
ficiency of CFTR can vary in different cell types (Varga
et al., 2004), but it is clear that CFTRDF508 does not
reach the native state and is degraded prematurely in
human airway cells (Kreda et al., 2005). CFTR and
CFTRDF508 appear to assume similar conformations
at early stages of assembly (Zhang et al., 1998), but
CFTRDF508 folding becomes arrested at a poorly de-
fined step.
Since F508 is located in a surface-exposed loop on
NBD1 that makes contacts with MSD1 in bacterial ABC
transporters, the loss of the F508 side chain may prevent
proper contact formation between NBD1 and MSD1 and
lead to misassembly of multiple regions in CFTR (Chang
and Roth, 2001). In addition, loss of F508 from the NBD1
backbone causes purified NBD1 to exhibit a tempera-
ture-sensitive folding defect (Thibodeau et al., 2005).
Thus, misfolding and misassembly of DF508 NBDI ap-
pear to cause CFTRDF508 to be targeted for degrada-
tion, but how ERQC detects such folding defects is not
clear.
Defects in the folding pathway of CFTRDF508 de-
scribed above suggest that it accumulates in a conforma-
tion that exposes nonnative surfaces in the cytosol as well
as in the ERmembrane. Cytosolic Hsc70 interacts with ER
membrane localized Hdj2, the U-box protein CHIP, and
the E2 UbcH5 to form a multisubunit E3 complex that
ubiquitinates cytosolic regions of CFTRDF508 (Meacham
et al., 1999, 2001; Younger et al., 2004). Yet, upon inacti-
vation of the Hsc70/CHIP E3 complex, CFTRDF508 is still
unable to escape the ER membrane and is degraded
(Younger et al., 2004). Thus, it is possible that additional
E2/E3 ubiquitin ligase complexes, which might monitor
the folded state of CFTR’s transmembrane domains, func-
tion in conjunction with the cytosolic Hsc70/CHIP E3 com-
plex to triage CFTR and CFTRDF508.
Studies in mammalian cells are yet to identify an ER-
localized E3 ubiquitin ligase that functions in ERAD of
CFTR. Nonetheless, there is evidence to suggest that a
tail-anchored and ER-localized E2 ubiquitin-conjugating
(Ubc) enzyme, Ubc6e, facilitates CFTR degradation
(Lenk et al., 2002). Ubc6e does not appear to interact
with the E3 CHIP to ubiquitinate CFTR (Younger et al.,
2004). Therefore, we sought to identify the cognate E3
ubiquitin ligase that functions with Ubc6e and then define
the role that this E2/E3 complex plays in QC of CFTR.
We identified the tail-anchored RING domain protein
RMA1/RNF5 (Didier et al., 2003; Matsuda et al., 2001) as
a component of an ER-associated E3 ubiquitin ligase
complex that contains Ubc6e and the transmembrane
quality-control factor Derlin-1 (Lilley and Ploegh, 2004;
Ye et al., 2004). The RMA1 E3 complex appears to sense
the assembly status of CFTR’s amino-terminal regions at
a folding step that occurs prior to NBDII synthesis and is
defective in CFTRDF508. The CHIP E3 appears to act after
NBDII synthesis and detects folding defects that involve
terminal steps in CFTR assembly.572 Cell 126, 571–582, August 11, 2006 ª2006 Elsevier Inc.RESULTS
RMA1 Cooperates with Ubc6e to Target CFTRDF508
for Degradation
To identify new QC checkpoints that function to triage
CFTR and CFTRDF508, we sought to identify factors
that function in ERQC with Ubc6e. We chose to investi-
gate whether the human homolog of Arabidopsis RMA1
(Didier et al., 2003; Matsuda et al., 2001) interacts with
Ubc6e to target CFTR and CFTRDF508 for proteasomal
degradation. RMA1 is a 180 amino acid residue tail-
anchored ER membrane protein that contains a cytoplas-
mic RING domain (Figure 1A). RMA1 colocalizes with
GFP-CFTRDF508 in the ER membrane (Figure 1B) and
cofractionates with the ER marker calnexin (Figure 1C).
In addition, the B form of CFTRDF508 (Figure 1D) and
CFTR (data not shown) coimmunoprecipitate in a complex
that containsmyc-RMA1. When the RING domain mutant
myc-RMA1 C42S was substituted formyc-RMA1 in trans-
fections, several-fold more CFTRDF508 coprecipitated
with the RMA1 mutant. Thus, RMA1 is an ER-localized
E3 protein that enters into complexes with CFTRDF508
(Figure 1D).
To determine whether RMA1 can divert CFTR from its
folding pathway and target it for degradation, the effect
that RMA1 overexpression had on the accumulation of
the immaturely glycosylated, nonnative B and maturely
glycosylated, folded C form of CFTR was determined
(Figure 2A). A 2-fold increase in RMA1 levels dramatically
reduced the steady-state level of the C form of CFTR, and
this action was not accompanied by the accumulation of
the B form (Figure 2A). Treatment of cells with the pro-
teasome inhibitor ALLN prevented RMA1 from reduc-
ing CFTRDF508 levels and caused a large quantity of
CFTRDF508, which would normally have been degraded,
to accumulate as an ubiquitin conjugate (Figure 2B).
Pulse-chase analysis showed that elevation of RMA1
caused a 60% reduction in the accumulation of
35S-CFTR and 35S-CFTRDF508 during the 20 min pulse-
labeling period (Figure 2C). Then, in the chase period,
RMA1 blocked the glycolytic maturation of CFTR and
accelerated degradation of the CFTRDF508 B form
around 2-fold. The ability of RMA1 to divert the B form
of CFTR and CFTRDF508 from its folding pathway was
lost when RMA1 C42S or RMA1DTM was substituted for
RMA1 in cotransfections (Figure 2D).
When RMA1 and Ubc6e levels were reduced by treat-
ment of cells with siRNA oligonucleotides, CFTRDF508
levels increased nearly 4-fold, and this effect correlated
with reduced expression of RMA1 and Ubc6e (Figure 2E).
Thus, RMA1 is an ER-localized RING E3 that can be iso-
lated in coprecipitates with the B form of CFTR, and the
modulation of its activity influences the fate of nascent
CFTR and CFTRDF508.
Data generated thus far indicate that RMA1 is a compo-
nent of an ERQC complex that degrades CFTR and
CFTRDF508 equally well. However, it remained possible
that the deletion of DF508 causes more nascent
CFTRDF508 than CFTR to accumulate in a conformation
that is recognized by RMA1 and/or its interacting partners.
To explore this possibility, we compared the sensitivity of
CFTR and CFTRDF508 to elevation of RMA1 again, but
Figure 1. RMA1 Is an ER Membrane-Associated E3 Ubiquitin
Ligase that Coprecipitates with CFTRDF508
(A) The predicted domain structure of RMA1. C42 is a residue in the
RING domain that is required for RMA1 ubiquitin ligase activity. TM de-
notes the transmembrane region, and N- and C- identify the amino-
and carboxy-terminal ends of RMA1, respectively.
(B) Colocalization of myc-RMA1 and GFP-CFTRDF508 in transiently
transfected HEK293 cells by fluorescence microscopy.
(C) Fractionation of RMA1 with membranes that contain the ERmarker
calnexin. Cell extracts were prepared and subjected to differential cen-
trifugation and probed for the presence ofmyc-RMA, calnexin, Hsc70,
and BiP by Western blot. Where indicated, membranes that pelleted
when extracts were spun at 100,000 3 g were washed with 0.5 M
NaCl or resuspended in 0.1%SDS and then reisolated. S and P denote
the supernatant and pellets of centrifuged samples.
(D) RMA1 and CFTRDF508 can be coprecipitated with each other.
CFTRDF508 was coexpressed with myc-RMA1 or myc-RMA1C42S,
and extracts from 35S-labeled HEK293 cells were prepared in PBS
supplemented with 0.1% Triton X-100. Coimmunoprecipitations
were carried out with a-myc, and then CFTRDF508 was reimmunopre-
cipitated with a-CFTR. Autoradiographs of bands corresponding to
RMA1 and CFTRDF508 are shown.reduced the level of RMA1 by utilizing 0.5 mg of RMA1
expression plasmid instead of 1.0 mg (Figure 3A). Under
these conditions, RMA1 overexpression only reduced
CFTR levels by 30%, but CFTRDF508 accumulation
was reduced by 90%. Thus, triage of CFTRDF508 is
more sensitive to elevation of RMA1 activity than CFTR.
Yet, since RMA1 promotes the degradation of both
CFTR and CFTRDF508, it is not likely that the RMA1 E3
can sense a true difference in the conformation of these
proteins. Instead, it is likely that the folding of a larger por-
tion of nascent CFTRDF508 than nascent CFTR arrests at
a stage where its nonnative conformation can be recog-
nized by components of the RMA1 E3 complex.
To evaluate the range of proteins that are selected for
ERAD by RMA1, the sensitivities of CFTRDF508, TCRa,
and ApolipoB48 to RMA1 overexpression were compared
(Figure 3B–C). The steady-state level of the B form of
CFTRDF508was reduced by85%when cells were trans-
fected with 1 mg of pcDNA-RMA1. Under these same con-
ditions, the accumulation of TCRa and ApoB48 was
largely unaffected. Yet, when cells were transfected with
3 mg of pcDNA-RMA1, a decrease in the steady-state
levels of TCRa and ApoB48 was observed (Figure 3A). De-
creased steady-state levels of TCRa and ApoB48 resul-
tant from RMA1 overexpression correlated with a 2-fold
increase in the degradation rates of these proteins (Fig-
ures 3C and 3D). The observed differences in the sensitiv-
ities of CFTRDF508, TCRa, and ApoB48 to alterations in
RMA1 levels indicates that RMA1 overexpression does
not cause the pleiotropic degradation of ERAD substrates.
However, it is difficult to judge the relative concentrations
of these respective ERAD substrates in the cell, so it is
premature to conclude that the RMA1 E3 can selectively
recognize different classes of ERAD substrates.
To determine whether RMA1 and Ubc6e functionally
interact, we analyzed whether they could act jointly to
enhance CFTRDF508 degradation (Figure 4). Individual
levels of Ubc6e and RMA1 were adjusted to reduce
CFTRDF508 accumulation by 50%–60%. When RMA1
and Ubc6e were coexpressed at this same level, there
was a dramatic reduction in CFTRDF508 accumulation
(Figures 4A and 4C). The RING domain mutant RMA1
C42S and the Ubc domain mutant Ubc6e C91S were un-
able to substitute for their wild-type counterparts and re-
duce the steady-state level of CFTRDF508. Thus, RMA1
and Ubc6e appear to cooperate in a RING domain- and
Ubc domain-dependent manner to degrade CFTR.
The purified RING domain of RMA1 can interact with
Ubc5 to promote polyubiquitin chain assembly (Matsuda
et al., 2001). Therefore, we determined whether or not
RMA1 could cooperate with UbcH5a to modulate
CFTRDF508 levels in cultured cells (Figure 4B). The com-
bined overexpression of RMA1 and UbcH5a did not result
in a synergistic reduction in the steady-state levels of
CFTRDF508 (Figures 4B and 4D). In addition, pulse-chase
analysis revealed that the combined expression of RMA1
and UbcH5a did not reduce the accumulation of CFTR be-
yond that observed when only RMA1 activity was elevatedCell 126, 571–582, August 11, 2006 ª2006 Elsevier Inc. 573
Figure 2. RMA1 Promotes the Degrada-
tion of CFTR and CFTRDF508
(A) Overexpression of RMA1 reduces the
steady-state level of CFTR. Western blots of
extracts prepared from cells in which myc-
RMA1 (pCDNA3.0-mycRMA1, 1.0 mg) was
coexpressed with CFTR.
(B) Reduction of CFTRDF508 levels by RMA1 is
blocked by ALLN. CFTRDF508 was coex-
pressed with RMA1, and ALLN (200 mM) was
added to cells 4 hr prior to lysis. Extracts
were prepared in lysis buffer supplemented
with 5 mM N-ethyl maleimide, and the protein
concentration of extracts was determined
with a detergent-compatible Bradford assay.
CFTRD F508 was then immunoprecipitated
from 30 mg of protein extract. Immunoprecipi-
tates were then probed for the presence of
CFTRDF508 or ubiquitin by Western blot.
(C) The effect of RMA1 on the kinetics of CFTR
and CFTRDF508 biogenesis. Cells were la-
beled with 35S-translabel for 20 min, and after
a given chase period, CFTR or CFTRDF508
was immunoprecipitated and processed for
autoradiography. Values from quantitation of
CFTR and CFTRDF508 represent the percent-
age of the B form of CFTR and CFTRDF508
that was present at t = 0. Values are represen-
tative of two experiments, and the quantitation
displayed is from the data shown in the above
panels.
(D) Steady-state levels of CFTR and
CFTRDF508 when coexpressed with wild-
type or mutant forms of RMA1.
(E) Steady-state levels of CFTRDF508 were de-
termined 24 hr after cotransfection with siRNA
duplexes (50 nM) against a nonspecific mRNA,
RMA1, or Ubc6e. As a control, the ability of
these siRNAs to block the expression of
RMA1 or Ubc6e when cells were transfected
with 0.25 mg of pcDNA3.1(+)-RMA1 or Ubc6e
was determined. Western blots of calnexin
(CNX) or Hsc70 serve as gel loading controls.(Figure 4E). In contrast, the coexpression of RMA1 and
Ubc6e synergistically reduced the quantity of 35S-labeled
CFTRDF508 that accumulated during a 20 min labeling pe-
riod (Figure 4F). When similar experiments were conducted
with CFTR, nearly identical results were observed (data not
shown). These collective data support the conclusion that
RMA1 and Ubc6e form a specific E2/E3 pair that selects
nascent CFTR and CFTRDF508 for degradation.
The pulse-chase analysis of CFTR and CFTRDF508 bio-
genesis (Figures 2 and 4E) shows that significantly less of
the B form of these proteins accumulates when RMA1 ac-
tivity is increased. Therefore, it is possible that RMA1 and574 Cell 126, 571–582, August 11, 2006 ª2006 Elsevier Inc.Ubc6e recognize folding defects in CFTRDF508 during or
soon after translation. Alternatively, the coexpression of
RMA1 and Ubc6e with CFTRDF508 might simply reduce
its expression level. To address these questions, we ex-
amined the effect of RMA1 and Ubc6e on CFTRDF508
biosynthesis in the absence and presence of the protea-
some inhibitor ALLN (Figure 4F). 35S-CFTRDF508 accu-
mulated with time over the course of a 20 min labeling
period, and ALLN was observed to increase the accumu-
lation of CFTRDF508 around 2-fold at every time point.
Yet, in cells where RMA1 or RMA1 and Ubc6e were over-
expressed, the accumulation of CFTRDF508 was reduced
Figure 3. Comparison of the Sensitivity
of Different ERAD Substrates to Eleva-
tion of RMA1 Activity
(A) A side-by-side comparison of the sensitivity
of CFTR and CFTRDF508 to a lower level of
RMA1 overexpression. Instead of cotransfect-
ing cells CFTR and CFTRDF508 expression
plasmids and 1.0 mg of pCDNA3.0-myc-
RMA1 as in Figures 1 and 2, cells were trans-
fected with CFTR expression plasmids and
0.5 mg of pCDNA3.0-myc-RMA1.
(B) The influence of RMA1 overexpression on
CFTRDF508, TCRa, and Apolipoprotein B48
levels. The indicated ERAD substrates were
expressed alone or with pcDNA-RMA1 (1.0 or
3.0 mg). The steady-state level of the indicated
protein was determined 18 hr posttransfection
by Western blot.
(C) Quantitation of the steady-state levels of
CFTRDF508, TCRa, and Apolipoprotein B48
from autoradiographs shown in panel (A).
(D) Kinetics of Apolipoprotein B48 and TCRa
degradation. Where indicated, cells were
cotransfected with 3.0 mg of pcDNA3.1(+)-
RMA1. Cells were labeled with 35S-translabel
for 20 min and chased for the indicated times.
Levels of immunoprecipitated Apolipoprotein
B48 or TCRa were expressed as a percentage
of the total amount present at t = 0.at all time points. However, the coexpression of RMA1 and
Ubc6e did not hinder synthesis of CFTRDF508, because
treatment of cells with ALLN restored the labeling of
CFTRDF508 to a level that was greater than that observed
in the control. Thus, a large portion of CFTRDF508 ap-
pears to be degraded cotranslationally, and the RMA1/
Ubc6e E3 complex appears capable ofmediating this pro-
cess. Our interpretations of the data presented in Figure 4
are consistent with the finding that CFTR can be ubiquiti-
nated cotranslationally (Sato et al., 1998). Yet, whether
RMA1 and Ubc6e truly act cotranslationally and ubiquiti-
nate CFTR andCFTRDF508while it is attached to the ribo-
some requires further study.
Derlin-1 Interacts with RMA1 and Ubc6e to Facilitate
CFTR Degradation
RING domain E3 ubiquitin ligases such as RMA1 are typ-
ically members of multisubunit complexes in which they
serve as scaffolds that link the ubiquitin-conjugating activ-
ity of an E2 to the substrate-binding activity of a specific
effecter molecule (Hershko and Ciechanover, 1998).
Thus, it is plausible that RMA1 promotes CFTR degrada-
tion by functioning in a complex that contains a mem-
brane-inserted substrate selector that senses the folded
state of CFTR (Figure 5). The ERQC factor Derlin-1 con-tains four transmembrane-spanning domains and is
known to form complexes with different transmembrane
E3s and a number of other ERQC factors and appears to
have multiple functions in ERAD (Katiyar et al., 2005; Lilley
and Ploegh, 2005; Schuberth and Buchberger, 2005; Ye
et al., 2005). Therefore, we tested whether Derlin-1 might
be involved in the selection of CFTR for degradation by
modulating Derlin-1 activity and determining the effect
this had on CFTR biogenesis.
Elevation of Derlin-1 levels by 3-fold led to the reten-
tion of the B form of CFTR in the ER (Figures 5A and
5B). HA-Derlin-1 formed coimmunoprecipitable com-
plexes with the newly synthesized B form of CFTR
(Figure 5C). Derlin-1 was also found to remain associated
with the pool of B form that was retained in the ERwhen its
activity was elevated to the point where it blocked CFTR
folding by 50% (Figure 5C). Under these same experi-
mental conditions, complex formation between HA-Der-
lin-1 and the C form of CFTR was not observed. In addi-
tion, HA-Derlin-1 was also demonstrated to enter into
coimmunoprecipitable complexes with CFTR370X, which
represents MSDI of CFTR (Figure 5D). Eight percent of the
total immunoprecipitable CFTRDF508 and 12% of the
total immunoprecipitable CFTR370X present in cells was
coprecipitated with HA-Derlin-1 (see the legend toCell 126, 571–582, August 11, 2006 ª2006 Elsevier Inc. 575
Figure 4. RMA1 Cooperates with Ubc6e
to Promote Degradation of CFTRDF508
(A and B) Western blots for CFTRDF508 that
was expressed alone or in combination with
the indicated Ubc and RMA1 (similar results
were observed when CFTR was utilized as a
substrate). Proteins in cell extracts were re-
solved on 8% SDS-PAGE gels, and Western
blots were decorated with the indicated
antibody.
(C and D) Western blots of cell extracts that
show the expression level of different forms of
FLAG-RMA1 and myc-Ubc6e or myc-UbcH5a
when they were coexpressed with CFTRDF508.
Proteins in cell extracts were resolved on
12.5% SDS-PAGE gels, and Western blots
were decorated with the indicated antibody
against Myc or FLAG epitopes.
(E) RMA1 and Ubc6e cooperate to promote
CFTRDF508 degradation. CFTRDF508was im-
munoprecipitated from 35S-labeled cells at the
beginning and end of a 20 min chase period
and detected by autoradiography.
(F) Synthesis of 35S-CFTRDF508 under the
indicated conditions. When present, ALLN
(200 mM) was added to cell culture media 1 hr
before the addition of 35S-translabel. Bands
were quantitated by laser densitometry and
are expressed as a percentage of total
CFTRDF508 present at t = 0 in the control.Figure 5). The level of complex formation detected be-
tween Derlin-1 and either CFTR or CFTR370X is similar
to the quantity of CFTR that coprecipitated with Hsc70
(Meacham et al., 1999). It should also be noted that the
level of CFTR:Derlin-1 complexes detected is likely to rep-
resent an underestimation of the total level of complex for-
mation that occurs in the cell because Derlin-1:substrate
complexes are expected to dissociate upon dilution dur-
ing isolation protocols.
The retrotranslocation factor p97 is known to be present
in complexes that contain Derlin-1 and E3 ubiquitin ligases
(Ye et al., 2005; Lilley and Ploegh, 2005), and we observed
it to coprecipitatewith Derlin-1 andCFTR370X (Figure 5D).576 Cell 126, 571–582, August 11, 2006 ª2006 Elsevier Inc.The presence of p97 in a complex with Derlin-1 and a
CFTR biogenic intermediate implies that the retention of
CFTR in the ER is coupled to its ubiquitination by RMA1
and Ubc6e and retrotranslocation.
If Derlin-1 plays an active role in the retention of nonna-
tive CFTR in the ER, then the reduction of its cellular activ-
ity should allow more CFTR to escape the ER and accu-
mulate in its C form. Indeed, the treatment of cells with
Derlin-1 siRNAs enabled 2-fold more of the folded C
form of CFTR and the nonnative B form of CFTRDF508
to accumulate (Figure 5E). These collective data demon-
strate that the positive and negative modulation of Der-
lin-1 activity reciprocally modulates the partitioning of
Figure 5. Derlin-1 Retains the B Form of CFTR in the ER
(A) Pulse-chase analysis of CFTR biogenesis in the presence or ab-
sence of transiently expressed Derlin-1 [pcDNA3.1(+)-HA-Derlin-1,
0.05 mg]. Cells were labeled for 20 min with 35S-translabel and then
lysed under nonnative conditions. The protein concentration in cell ex-
tracts was determined, and CFTR was immunoprecipitated from 30 mg
of total extract protein.
(B) Western blot showing the expression level of endogenous Derlin-1
relative to overexpressed HA-Derlin-1.
(C) The B form of CFTR coimmunoprecipitates with HA-Derlin-1. CFTR
was expressed alone or with HA-Derlin-1 [pcDNA3.1(+)-HA-Derlin-1,
0.025 mg], and extracts of 35S-labeled cells were prepared and splitCFTR between folding and degradation pathways. The
exact mechanism for Derlin-1 function in retaining CFTR
in the ER is not clear, but it appears to involve complex for-
mation with the membrane-spanning domains of CFTR.
Thus, Derlin-1 appears capable of functioning as a compo-
nent of the substrate selector for the RMA1/Ubc6e E3
ubiquitin ligase complex.
To determine whether Derlin-1 cooperates with RMA1
and Ubc6e to mediate QC of CFTR, the ability of these dif-
ferent ER membrane proteins to physically and function-
ally interact was examined (Figure 6). Extracts of cells
were prepared from 35S-labeled cells that coexpressed
FLAG-RMA1 with myc-Ubc6e, HA-Derlin-1, and
CFTRDF508 under native buffer conditions. Then FLAG-
RMA1 was immunoprecipitated and found to specifically
associate with a number of different radiolabeled proteins.
Ubc6e, Derlin-1, and CFTRDF508 were identified as inter-
action partners of RMA1 via their reimmunoprecipitation
from the RMA1 coprecipitate (Figure 6A). Complex forma-
tion between these proteins and RMA1 appeared specific,
as we were unable to detect Sec61, Erdj4, or calnexin in
products of RMA1 or Derlin-1 coprecipitation reactions
(data not shown). Ubc6e and Derlin-1 also appeared
to functionally interact to promote degradation of
CFTRDF508, because their combined expression
after the indicated chase time. CFTR was immunoprecipitated under
denaturing conditions from one portion of the cell extract with
a-CFTR. HA-Derlin-1 was immunoprecipitated from the other portion
under native buffer conditions, and the quantity of CFTR that copreci-
pitated was determined by reimmunoprecipitating CFTR from HA-
Derlin-1 immunoprecipitates. The band marked with a * denotes
a background band that precipitates with protein-G beads. Direct im-
munoprecipitations of CFTR were carried out with 30 mg of cell extract
protein as the starting material, and HA-Derlin-1 coimmunoprecipita-
tions were conducted with 120 mg of cell extract. Gels shown in the
panels were exposed to X-ray film for the same time. The quantity of
the B form of CFTR observed to nonspecifically precipitate with a-
HA represents less than 1% of the total immunoprecipitable CFTR,
and the quantity of the B form of CFTR that coprecipitated with Der-
lin-1-HA at t = 0 and t = 3.0 of the chase period represents around
12% of total immunoprecipitable CFTR at each respective time point.
(D) CFTR370X can be coimmunoprecipitated with HA-Derlin-1. Cells
were transfected with CFTR370X and HA-Derlin-1 and radiolabeled
for 30 min. Extracts were prepared under native conditions and split.
In panels denoted IP, HA-Derlin-1 and CFTR370X were immunopre-
cipitated under nonnative conditions. In panels labeled Co-IP, HA-Der-
lin-1 was precipitated with a-HA antibody, and p97 and CFTR370X
present in the coprecipitates were identified by reimmunoprecipitation
(data not shown). Direct immunoprecipitations were conducted from
30 mg of cell extract, and coimmunoprecipitations utilized 120 mg of ex-
tract protein as starting material. Panels were exposed to X-Ray film
for the same time period, and CFTR370X that coprecipitated with
HA-Derlin-1 was calculated to be equivalent to 8% of total CFTR370X.
(E) Treatment of cells for 24 hr with siRNAi (50 nM) against Derlin-1
leads to increased expression of CFTR and CFTRDF508. Demonstra-
tion of the ability of siRNAs to block synthesis of HA-Derlin-1 ex-
pressed from pcDNA3.1(+)-HA-Derlin-1 was utilized as a control.
Where indicated, Western blots of tubulin and calnexin (CNX) levels
in cell extracts were used as load controls. Quantitation of bands on
gels is expressed either in raw densitometer units (panels [B] and [D])
or as a percentage of total B form of CFTR present at t = 0 (panel [A]).Cell 126, 571–582, August 11, 2006 ª2006 Elsevier Inc. 577
Figure 6. RMA1, Ubc6e, and Derlin-1 Functionally and Physi-
cally Interact to Promote Proteasome-Dependent Degrada-
tion of CFTRDF508
(A) CFTRDF508, HA-Derlin-1, andmyc-Ubc6e are present in a copreci-
pitable complex with FLAG-RMA1. Cells were labeled with 35S-trans-
label for 1 hr and solubilized in a buffer containing 0.1% Triton X-100.
Coimmunoprecipitations and reimmunoprecipitations were then car-
ried out as described in the Experimental Procedures section. Since578 Cell 126, 571–582, August 11, 2006 ª2006 Elsevier Inc.reduced the accumulation of 35S-CFTRDF508 to levels
that were 90% lower than the control and increased
CFTRDF508 turnover 2-fold (Figure 6B). Derlin-1, RMA1,
and Ubc6e appear to physically and functionally interact
to promote CFTR degradation.
It is possible that the reduction in CFTR accumulation
observed when components of the RMA1 E3 complex
were all jointly overexpressed is simply due to reduced
CFTRDF508 synthesis that is resultant from its coexpres-
sion with multiple proteins. However, the following obser-
vations indicate that elevation of the activity of the RMA1
E3 complex is the predominant cause for the reduced
accumulation of CFTRDF508 when RMA1, Ubc6e, and
Derlin-1 are jointly expressed. First, when RMA1, Derlin-
1, and Ubc6e were coexpressed, the cell is fully capable
of synthesizing CFTRDF508 because it accumulated
above control levels when the proteasome inhibitor
ALLN was present during cell labeling (Figure 6B). Sec-
ond, the expression levels of individual forms of these pro-
teins are not reduced by their joint coexpression (Figures
4C, 4D, and 6C). Thus, the data presented support amodel
for ERQC in which RMA1, Ubc6e, and Derlin-1 form an ER
membrane-associated E3 ubiquitin ligase complex that
acts alongside the cytosolic Hsc70/CHIP/UbcH5 E3 com-
plex to target the B form of CFTR and CFTRD508 for pro-
teasomal degradation (Figure 6D).
RMA1 and CHIP Promote the Degradation
of Different Regions of CFTR
Since components of the RMA1 E3 are membrane
inserted and expose their functional domains on the cyto-
solic face of the ER and components of the CHIP E3 com-
plex are cytosolic, we investigated whether they could
function to sense the folding status of different subdo-
mains of CFTR. This question was investigated by deter-
mining whether there were differences in the stage of bio-
genesis at which different-length CFTR and CFTRDF508
fragments that resemble translation intermediates be-
came sensitive to RMA1 or CHIP (Figure 7A). Cells were
transfected with quantities of CHIP and RMA1 expression
plasmids that led to a partial reduction in the steady-state
a large number of proteins in the 36 kDa molecular weight range pre-
cipitate with FLAG-RMA1, it is difficult to detect a signal for Ubc6e
above the background in the native immunoprecipitation. Yet, Ubc6e
was clearly present in RMA1 precipitates, because it could be reimmu-
noprecipitated from native precipitates under denaturing conditions.
(B) Coexpression of RMA1 and Ubc6e with Derlin-1 potentiates the
degradation of 35S-CFTRDF508. Total CFTRDF508 present at the
end of the 20 min labeling period was quantitated and is expressed
as a percentage of the total signal in the control. Changes in the levels
of CFTRDF508 during the course of the indicated chase reaction were
quantitated and expressed in percentage of the total signal at t = 0.
(C) Western blot analysis of transiently expressed HA-Derlin-1, FLAG-
RMA1, and myc-Ubc6e when these proteins are expressed individu-
ally and in concert with each other.
(D) Schematic diagram representing the E3 ubiquitin ligase complexes
that function to select CFTR and CFTRDF508 for proteasomal
degradation.
level of CFTR and CFTRDF508 (Figure 7B). CFTR370X
levels were partially reduced by RMA1, but were insensi-
tive to CHIP. CFTR593X, which is truncated near the end
of NBD1, was not detectable when RMA1 was overex-
pressed, but CHIP only reduced its expression level by
30%. CFTR1162X is truncated after MSDII and appears
to fold to a native-like conformation that is a poor sub-
strate for chaperones (Meacham et al., 1999). Consistent
with this interpretation, CFTR1162X was largely resistant
to the action of both RMA1 and CHIP. To our surprise, de-
letion of F508madeCFTR1162XDF508 sensitive to RMA1,
but not CHIP.
Figure 7. RMA1 and CHIP E3 Ubiquitin Ligases Exhibit Differ-
ences in Their Ability to Sense Folding Defects in CFTR
Mutants
(A) A model depicting the position in CFTR where stop codons or point
mutations were introduced to generate the tools utilized in panel (B).
(B) Steady-state levels of different-length CFTR fragments whenRMA1
and CHIP activity are elevated. Cells were transfected with pcDNA3.1
that expresses the indicated form of CFTR and pcDNA3.1-RMA1 or
pcDNA3.1-CHIP. The steady-state levels of CFTR and its different
fragments were determined by Western blot with an antibody that
specifically recognizes the N terminus of CFTR. Calnexin levels were
determined to serve as load controls. Quantitation of CFTR fragment
levels are expressed as percentage of control.Since the expression of MSDII reduced the sensitivity of
CFTR fragments to RMA1, it is possible that the RMA1 E3
complex acts to sense the assembly status of CFTR’s
transmembrane domains. If this is the case, then RMA1
should be able to detect defects in CFTR folding that are
caused by a disease-causing mutation in MSDI. Hence,
we compared the ability of RMA1 and CHIP to sense the
folding defect caused by the G91Rmutation in transmem-
brane helix I, which prevents proper assembly of CFTR
(Xiong et al., 1997). Indeed, CFTR1162X G91R was found
to be sensitive to elevation of RMA1 activity, but not to
CHIP. These data support the conclusion that the RMA1
and CHIP E3 complexes selectively interact with different
subdomains of CFTR.
DISCUSSION
The RING domain protein RMA1 has been identified as
a component of an ERmembrane-associated E3 ubiquitin
ligase complex that cooperates with the cytosolic Hsc70/
CHIP E3 complex to monitor the conformation of different
regions of nascent CFTR. The RMA1 QC checkpoint mon-
itors the assembly status of amino-terminal regions of
CFTR and appears to perform this function during or
soon after translation. The CHIP QC checkpoint inspects
the folding status of CFTR’s cytosolic domains, and
CFTR biogenic intermediates are most sensitive to CHIP
action after NBDII synthesis. Hence, the CHIP E3 appears
to play a posttranslational role in QC of CFTR.
Folding of CFTR and CFTRDF508 appears to progress
down similar pathways (Zhang et al., 1998), and both are
substrates of the RMA1 and CHIP E3 complexes. How-
ever, the deletion of F508 from NBD1 appears to cause
the folding of larger portion of nascent CFTRDF508 than
nascent CFTR to arrest in a conformation that is recog-
nized by the RMA1 checkpoint. Yet, the folding defect in
CFTRDF508 that is sensed by components of the RMA1
E3 complex is not insurmountable. However, forms
CFTRDF508 that escape the RMA1 checkpoint ultimately
fail QC at the CHIP checkpoint. Therefore, compounds
developed to correct disease-causing folding defects in
CFTR (Brown et al., 1996; Pedemonte et al., 2005) must
enable CFTRDF508 to pass through sequential QC check-
points that are staffed by ER membrane-inserted and
cytosolic E3 ubiquitin ligases.
The exact nature of the nonnative form(s) of CFTR and
CFTRDF508 that are recognized by components of the
RMA1 E3 complex is not clear. Nevertheless, several ob-
servations we made suggest that the RMA1 E3 complex
functions to detect folding defects related to the mis-
assembly of CFTR’s membrane-spanning domains. First,
the elevation of RMA1 activity drives the degradation of
CFTR biogenic intermediates that have the G91R muta-
tion in MSDI, which is degraded by ERAD due to defects
in MSD assembly (Xiong et al., 1997). Second, Derlin-1 re-
tains CFTR in the ER and does so via a mechanism that
may involve complex formation with MSDI. Finally, the
sensitivity of early-stage CFTR biogenic intermediates,Cell 126, 571–582, August 11, 2006 ª2006 Elsevier Inc. 579
which contain just MSDI and adjacent cytoplasmic do-
mains, to RMA1 is reduced upon expression of MSDII.
Since CFTRDF5081162X fails to attain a conformation
that is resistant to elevation of RMA1 activity, deletion of
F508 hinders the ability of MSDII to assemble into a com-
plex with amino-terminal regions of CFTR, which appear
to include MSDI (Chen et al., 2004).
The region in CFTR that is ubiquitinated by the Hsc70/
CHIP E3 are also unknown. Hsc70 is the substrate selec-
tor for the CHIP E3 complex (Younger et al., 2004) and can
cooperate with Hdj-2 to suppress the aggregation of puri-
fied NBD1 (Meacham et al., 1999). Thus, it was surprising
to observe that fragments of CFTR and CFTRDF508 that
contained just MSDI and NBD1 were relatively insensitive
to elevation of CHIP levels and that sensitivity to CHIP E3
activity was greatly increased after NBDII synthesis. Frag-
ments of CFTR that resemble early-stage biogenic inter-
mediates may be less sensitive to cytosolic CHIP than
RMA1 because CHIP cannot efficiently gain access to
misfolded regions that may be readily accessed by the
membrane-inserted components of the RMA1 E3 com-
plex. In contrast, NBDII is the last domain in CFTR to be
synthesized and might be more accessible to the CHIP
E3. In addition, the posttranslational folding of NBDII ap-
pears to be the rate-limiting step in CFTR folding, and
this process is defective in CFTRDF508 (Du et al., 2005).
Thus, it is logical that the Hsc70/CHIP E3 complex would
recognize forms of CFTR and CFTRDF508 in which NBDII,
and possibly other cytosolic domains, have failed to fold
or assemble efficiently.
The ubiquitin ligase of activity of the Hsc70/CHIP E3
complex has been reconstituted (Younger et al., 2004),
but the mechanism by which the RMA1 E3 complex binds
and ubiquitinates CFTR is unknown. Based on the data
presented, we propose the following two-stepmechanism
for RMA1 E3 function in the selection of CFTR for protea-
somal degradation. First, Derlin-1 may act alone or in
combination with other factors to scan the assembly sta-
tus of CFTR’s membrane domains. If MSDI and/or MSDII
fail to fold/assemble rapidly or correctly, then Derlin-1 en-
ters into a complex with CFTR. The CFTR that is associ-
ated with Derlin-1 is brought into association with RMA1
and Ubc6e. Subsequently, RMA1 and Ubc6e cooperate
to ubiquitinate a cytosolic region that is exposed in nonna-
tive CFTR, but is masked in on-pathway biogenic interme-
diates. Since DF508NBD1 is prone to misfolding (Thibo-
deau et al., 2005), it is possible that the binding of
Derlin-1 to MSDI is coupled to ubiquitination of regions
in DF508NBDI by RMA1 and Ubc6e.
The proposal that Derlin-1 binds misassembled CFTR
and brings it into contact with RMA1 and Ubc6e is based
on the following observations. First, Derlin-1 forms com-
plexes with the B form of CFTR and CFTRDF508, and it
can also be coimmunoprecipitated with MSDI of CFTR.
Complex formation between Derlin-1 and the B form of
CFTR correlates with the retention of CFTR in the ER. Sec-
ond, the modulation of the cellular activity of Derlin-1 influ-
ences the partitioning of CFTR between its folding and580 Cell 126, 571–582, August 11, 2006 ª2006 Elsevier Inc.degradation pathways. Yet, in contrast to studies with
RMA1 and Ubc6e, the elevation of Derlin-1 activity alone
does not lead to a dramatic reduction in the accumulation
of nascent CFTR. Instead, Derlin-1 appears to bind and
hold CFTR in the ER and requires interaction with addi-
tional factors, such as RMA1 and Ubc6e, to facilitate
CFTR degradation.
Whether Derlin-1 can directly bind to CFTR indepen-
dent of other cofactors is an open question. Nonetheless,
the ability of Derlin-1 to enter into complexes with nonna-
tive CFTR suggests that is has a chaperone-like activity
that allows it to function as a substrate selector for the
RMA1 E3 complex. This interpretation fitswell with several
recent studies that identify chaperone functions for mem-
brane proteins (Lord and High, 2005). The E. coli protein
YidC and its eukaryotic homologs function to suppress
the posttranslational aggregation of membrane proteins
and can facilitate protein folding and assembly reactions
(Dalbey and Kuhn, 2004). In addition, the ER membrane
protein INSIG-1 functions to recognize the conformational
state of HMG-CoA reductase and targets cholesterol
bound forms for ubiquitination by the transmembrane E3
gp78 (Song et al., 2005). The overexpression of INSIG-1
does not cause retention of CFTR in the ER (data not
shown), but its identification provides precedence for
a membrane protein serving as the substrate selector for
an ER-associated ubiquitin ligase.
RMA1 and Ubc6e are members of an expanding list of
ERQC factors that are isolated in complexes with Derlin-
1. The known interaction partners of Derlin proteins in-
clude VIMP (Ye et al., 2004), N-glycanase (Katiyar et al.,
2005), E3 ubiquitin ligases (Lilley and Ploegh, 2005; Ye
et al., 2005), EDEM (Oda et al., 2006), and the retrotrans-
location factor p97 (Lilley and Ploegh, 2004; Ye et al.,
2004). Since these cofactors are all implicated to function
in either substrate ubiquitination or retrotranslocation,
their interactions with Derlin appear to direct it to function
at multiple steps in the ERAD pathway. Based on the as-
sociation of Derlin-1 with p97, one function of Derlin-1 is
suggested to be that of a retrotranslocation channel (Ye
et al., 2004). CFTR degradation requires p97, but p97
acts after the selection of CFTR for ERAD, and overex-
pression of p97 does not cause CFTR to be retained in
the ER (Dalal et al., 2004). Yet, we have observed p97 to
coprecipitate with Derlin-1, CFTR370X, CFTR, and
CFTRDF508 (data not shown). Thus, Derlin-1 appears to
be a jack-of-all-trades that interacts with different ERQC
factors to couple its ability to retain CFTR in the ER with
CFTR’s ubiquitination and retrotranslocation.
EXPERIMENTAL PROCEDURES
Plasmids, Antibodies, and Miscellaneous Reagents
The plasmids utilized in this study for transfection of cultured cells were
described previously (Younger et al., 2004). RMA1 and Derlin-1 were
cloned by RT-PCR from total mRNA isolated from HEK293 cells and
inserted into pcDNA3.1(+). The antibodies used for Western blots
and/or immunoprecipitations were described previously (Younger
et al., 2004). a-RMA1 is a rabbit polyclonal antibody that was produced
against Gst-RMA1DTM purified from E. coli. The specificity of rabbit a-
RMA1 was authenticated by comparing its cross-reactivity to a mouse
monoclonal antibody against RMA1/RNF5 (Didier et al., 2003). siRNA
duplexes utilized in this study were purchased from Dharmacon.
Analysis of Protein Biogenesis
Culture of HEK293 cells for analysis of protein biogenesis was per-
formed as previously described (Younger et al., 2005). Cells were typ-
ically transfected with 1.0 mg of pcDNA3.1(+)-CFTR and 1.5 mg of
pcDNA3.1(+)-CFTRDF508. For coexpression experiments, RMA1,
Ubc6e, and UbcH5a were utilized at 0.25–0.5 mg/well of a 6-well plate.
pcDNA3.1(+)-HA-Derlin-1was introduced intocells at0.01–0.1mg/well.
The details of the protocols for 35S-labeling of cells, immunoprecipita-
tions, and Western blots are described elsewhere (Meacham and Cyr,
2002). When CFTR biogenesis was assessed by immunoprecipitation
from 35S-labeled cells, the protein concentration of lystates was deter-
mined, and immunoprecipitations were carried out with the same total
quantity of cell lysate protein (Meacham et al., 1999). When the steady-
state level of CFTR and CFTRDF508 was measured by Western blot,
levels of the marker protein Hsc70, tubulin, or calnexin in different
samples were compared as load controls. The colocalization of GFP-
CFTRDF508 with RMA1 was determined by fluorescence microscopy
(Younger et al., 2005).
Isolation of the RMA1/Ubc6e/Derlin-1 E3 Ubiquitin Ligase
Complex by Coimmunoprecipitation
Expression plasmids for CFTRDF508, FLAG-RMA1, myc-Ubc6e, and
HA-Derlin-1 were cotransfected into HEK293 cells, whichwere labeled
18 hr later with 35S-translabel for 1 hr. Cells from 6 individual wells of
a 6-well plate were pooled and lysed by incubation on ice at 4C in
500 ml of 150 mMNaCl, 50 mM phosphate, 1 mM phenylmethysulfonyl
fluoride (PMSF), 13 protease inhibitor cocktail(-)EDTA (Roche), 0.2%
BSA, and 0.1% Triton X-100. Immunoprecipitations were conducted
with cleared lysates using protein-G agarose beads that were pre-
coupled with a-FLAG antibody. Precipitates were washedwith a buffer
that was identical to the one previously described, except BSA was
omitted. Products of the coimmunoprecipitation reactions were ana-
lyzed by SDS-PAGE and fluorography. Verification of the identity of
35S-proteins in complexes isolated by coimmunoprecipitation was ac-
complished by reimmunoprecipitation of the indicated protein from
coimmunoprecipitates (Meacham et al., 1999).
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